A Rare Lymphoproliferative Disease: Castleman Disease
Nadir Bir Lenfoproliferatif Hastalık: Castleman Hastalığı

Eren Gündüz¹, Nihal Özdemir², Şule Mine Bakanay³, Sema Karakuş⁴
¹Eskişehir Osmangazi University Faculty of Medicine, Department of Hematology, Eskişehir, Turkey
²İstanbul University Medical School, Department of Hematology, İstanbul, Turkey
³Ankara Yıldırım Beyazıt University Medical School, Department of Hematology, Ankara, Turkey
⁴Başkent University Faculty of Medicine, Department of Hematology, Ankara, Turkey

Abstract

Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.

Keywords: Castleman disease, Diagnosis, Treatment

Introduction

Castleman disease (CD), also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia, was first reported by Benjamin Castleman in 1954. It is a rare disease diagnosed in 6600–7700 individuals each year in the United States [1,2].

CD is classified as unicentric CD (UCD), involving a single lymph node or a single region of nodes, and multicentric CD (MCD), involving multiple lymphatic regions [3]. UCD is more common [1] and has been reported to occur in younger individuals than MCD [4,5,6,7,8]. MCD can occur in any region of the body and has poorer prognosis.

MCD is further divided into three subgroups: human herpes virus-8 (HHV-8)-associated MCD; polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS)-associated MCD; and idiopathic MCD (iMCD) (Figure 1) [9].

Diagnosis

Standard investigations for CD usually begin with lymph node biopsy followed by radiological investigation, preferably with positron emission tomography/computed tomography (PET/CT), complete blood count, serum chemistry, markers of inflammation, serum cytokine levels, viral serology for HHV-8 and human immunodeficiency virus (HIV),...
protein electrophoresis, immunofixation, and quantitative immunoglobulins [10,11].

The diagnostic criteria for iMCD and TAFRO syndrome, explained below, are summarized in Table 1 [12]. Diagnosis of HHV-8-associated MCD requires HHV-8 detection and plasmablastic histopathologic findings on lymph node biopsy [13]. POEMS-associated MCD is diagnosed if only one of the two mandatory major criteria of polyneuropathy and monoclonal plasma proliferative disorder is present with lymph node biopsy diagnostic of CD [14].

### Differential Diagnosis

Autoimmune diseases (immunoglobulin G4-related disease, rheumatoid arthritis, systemic lupus erythematosus, adult-onset Still disease), neoplastic disorders (lymphoma, desmoid tumors, retroperitoneal sarcoma, paragangliomas, sarcomas, hemangiopericytoma, bronchial adenoma, neurofibroma, chest wall tumors, schwannoma), and infectious disorders (HAV, Epstein–Barr virus [EBV], cytomegalovirus, tuberculosis, toxoplasmosis) must be considered in the differential diagnosis [3,14,15,16,17,18,19].

### Pathogenesis

Excessive cytokine production underlies the pathogenesis of CD. UCD and POEMS-associated MCD are caused by somatic mutations in monoclonal stromal and plasma cells [20]. In HHV-8-associated MCD, HHV-8 leads to a viral cytokine storm driven by interleukin-6 (IL-6) [11,12,21,22]. The exact mechanism of iMCD is unknown, but elevated IL-6 associated with autoimmune mechanisms, ectopic cytokine secretion by tumor cells, and/or viral signaling by a non-HHV-8 virus have been proposed [23].

### Pathology

The types of CD (hyaline vascular or hypervascular, plasmacytic, and mixed) are characterized by distinctive lymphoid architectural changes in all nodal compartments. The hyaline vascular variant is the most common type of UCD. MCD is predominantly of the plasmacytic variant with a few cases showing plasmablastic characteristics (Table 2) [24].

### Table 1. Diagnostic criteria for idiopathic multicentric Castleman disease.

| Major criteria |  |
|----------------|---|
| 1. Lymph nodes with histopathologic features consistent with iMCD spectrum |  |
| 2. Enlarged lymph nodes (≥1 cm in short-axis diameter) in ≥2 lymph node regions |  |

| Minor criteria |  |
|----------------|---|
| Laboratory |  |
| 1. Elevated CRP or ESR |  |
| 2. Anemia |  |
| 3. Thrombocytopenia or thrombocytosis |  |
| 4. Hypoalbuminemia |  |
| 5. Renal dysfunction or proteinuria |  |
| 6. Polyclonal hypergammaglobulinemia |  |

| Clinical |  |
| 1. B symptoms |  |
| 2. Hepatomegaly or splenomegaly |  |
| 3. Fluid accumulation |  |
| 4. Eruptive cherry hemangiomatosis |  |
| 5. Violaceous papules |  |
| 6. Lymphocytic interstitial pneumonitis |  |

| Supporting features |  |
| 1. Elevated IL-6, VEGF, IgA, IgE, LDH, and/or B2M |  |
| 2. Reticulin fibrosis of bone marrow |  |
| 3. Disorders associated with iMCD: paraneoplastic pemphigus, bronchiolitis obliterans organizing pneumonia, autoimmune cytopenia, polyneuropathy, inflammatory myofibroblastic tumor |  |

| Exclusion criteria |  |
| 1. Infection: HHV-8, EBV, CMV, toxoplasmosis, HIV, active tuberculosis |  |
| 2. Autoimmune/autoinflammatory: systemic lupus erythematosus, rheumatoid arthritis, adult-onset Still disease, juvenile idiopathic arthritis, autoimmune lymphoproliferative syndrome |  |
| 3. Malignancy: lymphoma, multiple myeloma, POEMS syndrome, primary lymph node plasmacytoma, follicular dendritic cell sarcoma |  |

Diagnosis requires both major criteria and at least 2 of 11 minor criteria with 1 laboratory criterion

iMCD: Idiopathic multicentric Castleman disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IL-6: interleukin-6; VEGF: vascular endothelial growth factor; IgA: immunoglobulin A; IgE: immunoglobulin E; LDH: lactate dehydrogenase; B2M: beta-2 microglobulin; HHV-8: human herpesvirus-8; EBV: Epstein–Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; POEMS: polyneuropathy, organomegaly, monoclonal protein, and skin changes.
Clinical and Laboratory Features

UCD may be clinically silent and laboratory findings are typically unremarkable. On the other hand, MCD presents with diffuse lymphadenopathy, systemic inflammation, and organ dysfunction [25]. Comorbid malignancies, lymphoma in iMCD, and Kaposi sarcoma in HHV-8-associated MCD have been described [26,27,28]. Patients with MCD may demonstrate anemia, leukocytosis, thrombocytopenia, thrombocytosis, elevated C-reactive protein, elevated IL-6, elevated erythrocyte sedimentation rate, elevated IgG, hypoalbuminemia, renal dysfunction, and elevated liver enzymes [1,26]. Clinical and laboratory features of CD are summarized in Table 3.

Specific Presentations of Castleman Disease

Paraneoplastic Pemphigus

The presence of mouth ulceration is highly suggestive of pemphigus and the severity of the disease correlates with lung involvement. It is more frequent in the context of UCD [11].

POEMS Syndrome

POEMS syndrome refers to the presence of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin changes. Other frequent clinical findings are papilledema, pleural effusions, ascites, sclerotic bone lesions, and thrombocytosis [21].

TAFRO Syndrome

TAFRO syndrome corresponds to a subtype of iMCD characterized by thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O) [11]. The outcome may be worse than in other cases of iMCD and no specific treatment has

Table 2. Histopathology of Castleman disease.

| Histological subtypes         | Frequency (%) |
|-------------------------------|--------------|
|                               | Unicentric   | Multicentric |
| Hyaline vascular              | 75           | <10          |
| Mixed                         | <10          | 45           |
| Plasmacytic                   | 20           | 45           |

Table 3. Clinical and laboratory features of Castleman disease.

|                              | UCD           | iMCD NOS       | iMCD TAFRO     | POEMS-associated MCD | HHV-8-associated MCD |
|-------------------------------|---------------|----------------|----------------|----------------------|----------------------|
| Systemic symptoms (fever, sweating, weight loss, effusion, autoimmune, respiratory) | +/- None or compression | ++ And rarely peripheral neuropathy | +++ And anasarca | ++ And Kaposisarcoma |
| Lymphadenopathy               | Mostly central, frequently bulky | Peripheral and central, usually small | Peripheral and central, usually small | Peripheral and central, usually small |
| Organomegaly                  | +/-           | +++            | +++            | +++                  |
| Abnormal inflammation markers (ESR, CRP, cholinesterase, ferritin, albumin) | +/-           | +++            | +++ Procalcitonin is also elevated | +                   |
| Anemia, thrombocytopenia, abnormal liver function tests | +/-           | ++ Sometimes thrombocytosis | +++            | +/-                 |
| Hypergammaglobulinemia        | +/-           | +++            | +/-            | +, small M spike     |
| Renal dysfunction             | -             | +              | +++ Intraocular coagulation and fibrinolysis | +                   |
| Autoimmune phenomena          | Rare, but paraneoplastic pemphigus can be seen | ++ Autoimmune hemolytic anemia, paraneoplastic pemphigus, immune thrombocytopenia, interstitial lung disease | +/-              | DAT positivity 46%, monoclonal gammapathy 28% |
| Clinical course               | Benign        | Variable       | Very aggressive | Aggressive          |
| Lymphoma risk                 | +             | +              | +/-            | +/+                 |

UCD: Unicentric Castleman disease; iMCD NOS: idiopathic multicentric Castleman disease-not otherwise specified; iMCD TAFRO: idiopathic multicentric Castleman disease-thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly; POEMS MCD: multicentric Castleman disease-polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin changes; HHV-8: human herpes virus-8; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAT: direct antiglobulin test.
been identified [22]. Diagnostic criteria for TAFRO syndrome are summarized in Table 4.

**Hemophagocytic Lymphohistiocytosis**

MCD and especially HHV-8-related MCD may be characterized by hemophagocytic lymphohistiocytosis at the initial presentation or upon relapse [25,26].

**Autoimmune Cytopenia**

Autoimmune hemolytic anemia is a relatively frequent complication of MCD. Immune thrombocytopenia has been reported in 5% to 20% of MCD cases [25,27,28].

**Peripheral Neuropathy**

Demyelinating peripheral neuropathy is frequently observed with CD. There is no clear association between the severity of the peripheral neuropathy and the subtype of CD [29].

**Renal Involvement**

Renal involvement is frequently observed in MCD, mainly in the plasmacytic and mixed subtypes, being reported in up to 25% of MCD cases. Glomerular lesions, AA amyloidosis, and interstitial nephritis are the most common renal pathology findings [30].

**Treatment**

Surgical resection provides radical treatment for the majority of patients with UCD. Radiotherapy is an important alternative when surgical resection is contraindicated or technically difficult. Other treatment options are embolization, rituximab, or siltuximab/tocilizumab in the event of inflammation [23].

Treatment of MCD still remains complex because MCD is a rare clinical entity and there is a lack of randomized controlled trials. Multiple therapeutic approaches have been used, including conventional cytotoxic chemotherapy (single-agent or combined), antiviral treatment, glucocorticoids, thalidomide, interferon-alpha, and molecular targeted therapies. Determination of HHV-8 status is also important [10]. Therapeutic approaches for MCD are listed in Table 5.

The use of prednisone or other glucocorticosteroids will frequently ameliorate symptoms, partially improve lymphadenopathy, and correct laboratory abnormalities. However, the impact is generally temporary. Lasting remissions are rare and the disease persists for years or decades in many patients. The factors that influence treatment efficacy and outcome are not fully understood.
may require the long-term use of corticosteroids, increasing the risk of bacterial infections [31,32]. The use of corticosteroids alone may be better reserved as a temporary intervention in acute situations where more definitive therapy has not yet been decided or will be delayed [24].

Currently, chemotherapy is the first option for most symptomatic patients. However, data are insufficient to favor one treatment for all patients. Oral chlorambucil and cyclophosphamide have been effective and are generally well tolerated [23,31,33]. Vinblastine [10] and oral etoposide [13] may also have activity. Therapy with a single alkylating agent may be most appropriate for fragile patients or cases in which a prompt response is not required.

Combination chemotherapy regimens such as cyclophosphamide, vincristine, and prednisone or cyclophosphamide, doxorubicin, vincristine, and prednisone have significant activity [10,14,31]. When combination chemotherapy is used, patients need to be closely monitored because of the increased risk of infection. Patients with HIV-associated CD may be at especially high risk for complications with standard combination chemotherapy [34]. A treatment algorithm is shown in Figure 2 [34,35].

**Figure 2.** Treatment algorithm for idiopathic multicentric Castleman disease.

ECOG: Eastern Cooperative Oncology Group.

| Characteristic          | *Mild (2 of 5) | **Severe (2 of 5) |
|-------------------------|----------------|-------------------|
| 1. ECOG performance status | 0-1            | ≥2                |
| 2. Glomerular filtration rate | Normal         | <30 mL/min        |
| 3. Fluid retention      | Present         | Anasarca, ascites, or effusion |
| 4. Hemoglobin (g/dL)    | ≥10             | ≤8                |
| 5. Pulmonary involvement | Absent          | Present           |

*Percentages may not add up due to rounding.*
Conclusion

CD is a rare lymphoproliferative disease that can mimic many malignant and nonmalignant conditions. Lymph node biopsy is essential to establish a definitive diagnosis and greater awareness of the disease among clinicians would facilitate early diagnosis.

Authorship Contributions

Concept: E.G., N.Ö., Ş.M.B., S.K.; Design: E.G., N.Ö., Ş.M.B., S.K.; Literature Search: E.G.; Writing: E.G.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 2015;56:1252-1260.
2. Cervantes CE, Correa R. Castleman disease: a rare condition with endocrine manifestations. Cureus 2015;7:e380.
3. Bonekamp D, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimick. Radiographics 2011;31:1793-1807.
4. Jiang JP, Shen XF, Du JF, Guan WX. A retrospective study of 34 patients with unicentric and multicentric Castleman’s disease: experience from a single institution. Oncol Lett 2018;15:2407-2412.
5. Yu JY, Oh J, Kim KS, Kim YI, Lim SC, Kim YC, Choi YD, Kwon YS. Castleman’s disease presenting as a tracheal mass. Ann Thorac Surg 2014;97:1798-1800.
6. Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY, Sun KL. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 2010;27:1171-1178.
7. Luo JM, Li S, Huang H, Cao J, Xu K, Bi YL, Feng RE, Huang C, Qin YZ, Xu ZJ, Xiao Y. Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 2015;15:34.
8. Kligerman SJ, Auerbach A, Franks TJ, Galvin JR. Castleman disease of the thorax: clinical, radiologic, and pathologic correlation: from the radiologic pathology archives. Radiographics 2016;36:1309-1332.
9. Cronin DMP, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16:236-246.
10. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. Kaposis’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276-1280.
11. Slazar R, Munchi NC. Diagnosis of Castleman disease. Hematol Oncol Clin N Am 2018;32:53-64.
12. Koa B, Borja AJ, Aly M, Padmanabhan S, Tran J, Zhang V, Rozuljpotel C, Pierson SK, Tamakloe MA, Khor JS, Werner TJ, Fajgenbaum DC, Alavi A, Revheim ME. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging 2021;12:35-45.
13. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol 2001;66:148-150.
14. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-662.
15. Fajgenbaum DC, Ulldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RSM, Pierson S, Paesens M, Rossi JF, Ide M, Ruth J, Croglia M, Suarez A, Krymskaya V, Chadburn A, Collee G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fossa A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Eleniota–Johnson KSJ, Lim MS. International, evidence-based consensus diagnostic criteria for HHV-8-negative/follicular multicentric Castleman disease. Blood 2017;129:1646-1657.
16. Madan R, Chen JH, Trottman-Dickenson B, Jacobson F, Hunsaker A. The spectrum of Castleman’s disease: mimics, radiologic pathologic correlation and role of imaging in patient management. Eur J Radiol 2012;81:123-131.
17. Delaney SW, Zhou S, Mercari D. Castleman’s disease presenting as a parotid mass in the pediatric population: a report of 2 cases. Case Rep Otolaryngol 2015;2015:691701.
18. Oksenhendler E, Bouboul D, Fajgenbaum D, Mirouze A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gerard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 2018;180:206-216.
19. Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica 2019;104:444-455.
20. Kott R, Vincent I, Dulioust A, Peretti D, Taburet AM, Delfraissy JF, Goujard C. Life-threatening interaction between antiretroviral therapy and vinblitine in HIV-associated multicentric Castleman’s disease. Eur J Haematol 2006;76:269-271.
21. Royer B, Merlusca L, Abraham J, Musset L, Haroche J, Choquet S, Leleu X, Sebban C, Decaux O, Galicier L, Roussel M, Recher C, Banois A, Guichard J, Brissou JM, Godmer P, Hermoire O, Deplaque G, Facot T, Asli B, Leblond V, Perdier JP, Marolleau JP. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013;88:207-212.
22. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshiida I, Moro H, Niki K, Takai K, Matsue K, Kurosawa M, Higahara M, Saito A, Okamoto M, Yokota K, Hiraiwa S, Nakamura N, Nakao S, Yoshino T, Sato Y. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8 multicentric Castleman’s disease. Am J Hematol 2016;91:220-226.
23. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radio-therapy. Cancer 2001;92:670-676.
24. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol 2012;47:163-177.
25. Stebbing J, Nigan S, Ibrahim H, Charles P, Nelson M, Kelleher P, Naresh KN, Boer M. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multicentric Castleman’s disease. Clin Exp Immunol 2008;154:399-405.
26. Dossier A, Meignin V, Fieschi C, Bouboul D, Oksenhendler E, Galicier L. Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis 2013;56:833-842.
27. Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, Stebbing J, Nelson M. Clinical features and outcome in HIV associated multicentric Castleman’s disease. J Clin Oncol 2011;29:2481-2486.
28. Dong Y, Wang M, Nong L, Wang L, Cen K, Liu W, Zhu S, Sun Y, Liang Z, Li Y, Ou J, Qiu Z, Ren H. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 2015;169:834-842.
29. Naddaf E, Dispenzieri A, Mandrekar J, Mauermann ML. Clinical spectrum of Castleman disease-associated neuropathy. Neurology 2016;87:2457-2462.
30. London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gerard L, Oksenhendler E, Azoulay E, Galicier L. Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related multicentric Castleman disease. Br J Haematol 2017;178:486-488.
31. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-1216.

32. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255-266.

33. Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol 1993;20:636-647.

34. Dispenzieri A, Fajgenbaum DJ. Overview of Castleman disease. Blood 2020;135:1353-1364.

35. van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 2018;32:89-106.